根据子宫内膜癌风险组评估β-catenin和L1CAM表达的预后潜力
研究纳入335例子宫内膜癌患者,按Proactive Molecular Risk Classifier for Endometrial Cancer分组,用免疫组化评估β-catenin和L1CAM表达与临床病理特征及生存的关系。β-catenin和L1CAM表达率均为10.4%且互斥,β-catenin阳性是高-中危亚组中唯一与更差无进展生存相关的因素(p=0.001)。
要点
- β-catenin和L1CAM在子宫内膜癌中表达率均为10.4%,呈互斥模式。
- β-catenin表达与子宫内膜样组织学(p=0.035)和低肿瘤分级(p=0.045)相关。
- 高-中危亚组中β-catenin阳性是唯一与更差无进展生存相关的因素(p=0.001)。
核心结论
- 核β-catenin表达可能作为预测高-中危子宫内膜癌患者复发和指导治疗策略的潜在生物标志物。
研究设计与样本
- 共纳入335例子宫内膜癌患者,根据Proactive Molecular Risk Classifier for Endometrial Cancer进行风险分组。
- 采用免疫组化评估β-catenin和L1CAM表达,分析其与临床病理特征及生存的关联。
主要发现
- β-catenin和L1CAM在所有患者中的表达率均为10.4%,且呈互斥模式。
- β-catenin表达与子宫内膜样组织学(p=0.035)和低肿瘤分级(p=0.045)相关。
- L1CAM表达与非子宫内膜样组织学(p<0.001)、高肿瘤分级(p<0.001)、淋巴血管间隙浸润(p=0.006)和晚期FIGO分期(p=0.001)相关。
- β-catenin表达在NSMP组最常见(26/35,74.3%),其次为POLE-mut组(6/35,17.1%)和dMMR组(3/35,8.6%)。
- L1CAM表达在p53-abnormal组最常见(22/35,62.9%),其次为NSMP组(6/35,17.1%)、dMMR组(4/35,11.4%)和POLE-mut组(3/35,8.6%)。
关键数值与推荐
- 在全队列多变量分析中,β-catenin和L1CAM对无进展生存和总生存均无统计学显著性。
- 在高-中危亚组中,β-catenin阳性是唯一与更差无进展生存相关的因素(p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigate the prognostic role of β-catenin and L1 neuronal cell-adhesion molecule (L1CAM) according to risk groups in endometrial carcinomas (EC). METHODS: A total of 335 EC patients were classified according to the Proactive Molecular Risk Classifier for Endometrial Cancer. We evaluated the expression of ß-catenin and L1CAM using immunohistochemistry, and their association with clinicopathological characteristics and survival. RESULTS: The expressions of β-catenin and L1CAM were observed in 10.4% of all patients, respectively, and showed mutually exclusive pattern. While β-catenin expression was associated with endometrioid histology (p = 0.035) and low tumor grade (p = 0.045), L1CAM expression was associated with non-endometrioid histology (p < 0.001), high tumor grade (p < 0.001), lymphovascular space invasion (p = 0.006), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (p = 0.001). β-catenin expression was most frequent in the no specific molecular (NSMP) group (26/35, 74.3%), followed by the DNA polymerase-ε-mutated (POLE-mut) (6/35, 17.1%), and mismatch repair-deficiency (dMMR) (3/35, 8.6%). L1CAM expression was most frequent in the p53-abnormal group (22/35, 62.9%), followed by the NSMP (6/35, 17.1%), dMMR (4/35, 11.4%), and POLE-mut (3/35, 8.6%). Although both markers did not show statistical significance in multivariate analysis for both progression-free survival (PFS) and overall survival in entire cohort, β-catenin positivity was identified as the sole factor associated with worse PFS in the high-intermediate risk subgroup (p = 0.001). CONCLUSION: The expression of nuclear β-catenin may serve as a potential biomarker for predicting recurrence and guiding therapeutic strategies in high-intermediate risk EC patients.
引用
- Yoon H, Suh DH, Kim K, et al. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group. Gynecol Oncol. 2024. PMID: 38309030. doi:10.1016/j.ygyno.2024.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。